We monitored the dynamic changes in one pancreatic cancer patients (PanC03) during treatment by aligning the total copies of KRAS transcripts (obtained by following the modified workflow) and serum CA19‐9 levels (U mL−1) with CT images taken before and post‐treatment. Here, KRAS is linked to familial pancreatic carcinoma.